Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. IDM Pharma Inc was formed on 16th August 2005 following the business combination of Epimmune Inc and Immuno-Designed Molecules SA. IDM SA is now a wholly-owned subsidiary of IDM Pharma. In connection with the closing of the transactions, a 1-for-7 reverse stock split of all outstanding common stock, including the shares issued to the stockholders of IDM SA, was completed. As a result, the combined company has a market capitalisation of approximately US$83 million.

IDM is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer and chronic infectious diseases, while maintaining the patient's quality of life. The company uses the term "immunogenics" to describe its multifaceted approach to harnessing the power of the immune system.

Unlike conventional treatments for cancer, such as chemo and radiation therapy, immunogenic approaches offer the advantage of improved saftey. IDM has demonstrated that its products have low toxicity and are well tolerated by patients.

IDM has four core technologies: Immunotherapy - Cell Therapy, Epitope Identification System (EIS), PADRE and ImmunoStealth.